Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
735
archived clinical trials in
Thyroid Cancer

Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer
An Open Label, Two Stage, Phase II Study to Evaluate the Efficacy and Tolerability of ZD6474 in Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Carcinoma.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1344
mi
from
New Haven, CT
Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer
An Open Label, Two Stage, Phase II Study to Evaluate the Efficacy and Tolerability of ZD6474 in Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Carcinoma.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1344
mi
from
New Haven, CT
Click here to add this to my saved trials
Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer
An Open Label, Two Stage, Phase II Study to Evaluate the Efficacy and Tolerability of ZD6474 in Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Carcinoma.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1290
mi
from
New York, NY
Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer
An Open Label, Two Stage, Phase II Study to Evaluate the Efficacy and Tolerability of ZD6474 in Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Carcinoma.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1290
mi
from
New York, NY
Click here to add this to my saved trials
Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer
An Open Label, Two Stage, Phase II Study to Evaluate the Efficacy and Tolerability of ZD6474 in Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Carcinoma.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1051
mi
from
Durham, NC
Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer
An Open Label, Two Stage, Phase II Study to Evaluate the Efficacy and Tolerability of ZD6474 in Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Carcinoma.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1051
mi
from
Durham, NC
Click here to add this to my saved trials
Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer
An Open Label, Two Stage, Phase II Study to Evaluate the Efficacy and Tolerability of ZD6474 in Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Carcinoma.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
569
mi
from
Houston, TX
Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer
An Open Label, Two Stage, Phase II Study to Evaluate the Efficacy and Tolerability of ZD6474 in Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Carcinoma.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
569
mi
from
Houston, TX
Click here to add this to my saved trials
Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer
An Open Label, Two Stage, Phase II Study to Evaluate the Efficacy and Tolerability of ZD6474 in Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Carcinoma.
Status: Enrolling
Updated:  12/31/1969
Research Site
mi
from
Villejuif Cedex,
Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer
An Open Label, Two Stage, Phase II Study to Evaluate the Efficacy and Tolerability of ZD6474 in Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Carcinoma.
Status: Enrolling
Updated: 12/31/1969
Research Site
mi
from
Villejuif Cedex,
Click here to add this to my saved trials
A Follow-up Study of Women Evaluated and Treated for Infertility
Follow-Up Study of Women Evaluated and Treated for Infertility
Status: Enrolling
Updated:  12/31/1969
Columbia University
1290
mi
from
New York, NY
A Follow-up Study of Women Evaluated and Treated for Infertility
Follow-Up Study of Women Evaluated and Treated for Infertility
Status: Enrolling
Updated: 12/31/1969
Columbia University
1290
mi
from
New York, NY
Click here to add this to my saved trials
An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer
An International, Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMATM) Versus Placebo in Subjects With Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
372
mi
from
Little Rock, AR
An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer
An International, Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMATM) Versus Placebo in Subjects With Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
372
mi
from
Little Rock, AR
Click here to add this to my saved trials
An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer
An International, Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMATM) Versus Placebo in Subjects With Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1339
mi
from
San Francisco, CA
An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer
An International, Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMATM) Versus Placebo in Subjects With Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1339
mi
from
San Francisco, CA
Click here to add this to my saved trials
An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer
An International, Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMATM) Versus Placebo in Subjects With Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
402
mi
from
Aurora, CO
An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer
An International, Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMATM) Versus Placebo in Subjects With Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
402
mi
from
Aurora, CO
Click here to add this to my saved trials
An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer
An International, Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMATM) Versus Placebo in Subjects With Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1344
mi
from
New Haven, CT
An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer
An International, Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMATM) Versus Placebo in Subjects With Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1344
mi
from
New Haven, CT
Click here to add this to my saved trials
An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer
An International, Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMATM) Versus Placebo in Subjects With Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1053
mi
from
Jacksonville, FL
An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer
An International, Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMATM) Versus Placebo in Subjects With Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1053
mi
from
Jacksonville, FL
Click here to add this to my saved trials
An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer
An International, Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMATM) Versus Placebo in Subjects With Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
610
mi
from
Chicago, IL
An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer
An International, Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMATM) Versus Placebo in Subjects With Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
610
mi
from
Chicago, IL
Click here to add this to my saved trials
An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer
An International, Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMATM) Versus Placebo in Subjects With Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
725
mi
from
Lexington, KY
An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer
An International, Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMATM) Versus Placebo in Subjects With Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
725
mi
from
Lexington, KY
Click here to add this to my saved trials
An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer
An International, Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMATM) Versus Placebo in Subjects With Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1444
mi
from
Boston, MA
An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer
An International, Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMATM) Versus Placebo in Subjects With Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1444
mi
from
Boston, MA
Click here to add this to my saved trials
An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer
An International, Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMATM) Versus Placebo in Subjects With Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
841
mi
from
Detroit, MI
An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer
An International, Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMATM) Versus Placebo in Subjects With Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
841
mi
from
Detroit, MI
Click here to add this to my saved trials
An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer
An International, Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMATM) Versus Placebo in Subjects With Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
515
mi
from
Rochester, MN
An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer
An International, Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMATM) Versus Placebo in Subjects With Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
515
mi
from
Rochester, MN
Click here to add this to my saved trials
An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer
An International, Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMATM) Versus Placebo in Subjects With Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
726
mi
from
Cincinnati, OH
An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer
An International, Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMATM) Versus Placebo in Subjects With Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
726
mi
from
Cincinnati, OH
Click here to add this to my saved trials
An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer
An International, Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMATM) Versus Placebo in Subjects With Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1383
mi
from
Portland, OR
An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer
An International, Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMATM) Versus Placebo in Subjects With Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1383
mi
from
Portland, OR
Click here to add this to my saved trials
An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer
An International, Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMATM) Versus Placebo in Subjects With Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1064
mi
from
Charleston, SC
An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer
An International, Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMATM) Versus Placebo in Subjects With Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1064
mi
from
Charleston, SC
Click here to add this to my saved trials
An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer
An International, Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMATM) Versus Placebo in Subjects With Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
569
mi
from
Houston, TX
An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer
An International, Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMATM) Versus Placebo in Subjects With Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
569
mi
from
Houston, TX
Click here to add this to my saved trials
An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer
An International, Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMATM) Versus Placebo in Subjects With Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1356
mi
from
Burlington, VT
An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer
An International, Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMATM) Versus Placebo in Subjects With Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1356
mi
from
Burlington, VT
Click here to add this to my saved trials
An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer
An International, Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMATM) Versus Placebo in Subjects With Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Research Site
8648
mi
from
St Leonards,
An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer
An International, Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMATM) Versus Placebo in Subjects With Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Research Site
8648
mi
from
St Leonards,
Click here to add this to my saved trials
An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer
An International, Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMATM) Versus Placebo in Subjects With Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
418
mi
from
Saint Louis, MO
An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer
An International, Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMATM) Versus Placebo in Subjects With Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
418
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Lesion Dosimetry With 124-Iodine in Metastatic Thyroid Carcinoma
Lesion Dosimetry With 124-Iodine in Metastatic Thyroid Carcinoma
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
1289
mi
from
New York, NY
Lesion Dosimetry With 124-Iodine in Metastatic Thyroid Carcinoma
Lesion Dosimetry With 124-Iodine in Metastatic Thyroid Carcinoma
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
1289
mi
from
New York, NY
Click here to add this to my saved trials
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Banner MD Anderson Cancer Center
841
mi
from
Gilbert, AZ
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Banner MD Anderson Cancer Center
841
mi
from
Gilbert, AZ
Click here to add this to my saved trials
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
University of California at San Francisco
1341
mi
from
San Francisco, CA
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
University of California at San Francisco
1341
mi
from
San Francisco, CA
Click here to add this to my saved trials
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
University of Colorado Denver
402
mi
from
Aurora, CO
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
University of Colorado Denver
402
mi
from
Aurora, CO
Click here to add this to my saved trials
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
UF Health Cancer Center
1049
mi
from
Gainesville, FL
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
UF Health Cancer Center
1049
mi
from
Gainesville, FL
Click here to add this to my saved trials
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
University of Kentucky
725
mi
from
Lexington, KY
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
University of Kentucky
725
mi
from
Lexington, KY
Click here to add this to my saved trials
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins University
1148
mi
from
Baltimore, MD
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins University
1148
mi
from
Baltimore, MD
Click here to add this to my saved trials
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
1443
mi
from
Boston, MA
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
1443
mi
from
Boston, MA
Click here to add this to my saved trials
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Weill Cornell Medicine
1289
mi
from
New York, NY
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Weill Cornell Medicine
1289
mi
from
New York, NY
Click here to add this to my saved trials
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Greenville Health System
880
mi
from
Greenville, SC
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Greenville Health System
880
mi
from
Greenville, SC
Click here to add this to my saved trials
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Texas Oncology P.A.
mi
from
Fort Worth, TX
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Texas Oncology P.A.
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Huntsman Cancer Institute
777
mi
from
Salt Lake City, UT
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Huntsman Cancer Institute
777
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Virginia Cancer Specialists, PC
1114
mi
from
Fairfax, VA
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Virginia Cancer Specialists, PC
1114
mi
from
Fairfax, VA
Click here to add this to my saved trials
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Compass Oncology
mi
from
Vancouver, WA
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Compass Oncology
mi
from
Vancouver, WA
Click here to add this to my saved trials
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic
840
mi
from
Phoenix, AZ
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic
840
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
H. Lee Moffitt Cancer Center & Research Institute
1112
mi
from
Tampa, FL
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
H. Lee Moffitt Cancer Center & Research Institute
1112
mi
from
Tampa, FL
Click here to add this to my saved trials
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
The Mayo Clinic
515
mi
from
Rochester, MN
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
The Mayo Clinic
515
mi
from
Rochester, MN
Click here to add this to my saved trials
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Oregon Health and Science University
1383
mi
from
Portland, OR
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Oregon Health and Science University
1383
mi
from
Portland, OR
Click here to add this to my saved trials
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Mary Crowley Cancer Research Center
347
mi
from
Dallas, TX
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Mary Crowley Cancer Research Center
347
mi
from
Dallas, TX
Click here to add this to my saved trials
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Sarah Cannon Research Institute
408
mi
from
Denver, CO
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Sarah Cannon Research Institute
408
mi
from
Denver, CO
Click here to add this to my saved trials
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
M.D. Anderson Cancer Center
572
mi
from
Houston, TX
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
M.D. Anderson Cancer Center
572
mi
from
Houston, TX
Click here to add this to my saved trials
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Cedars-Sinai Medical Center
1168
mi
from
Los Angeles, CA
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Cedars-Sinai Medical Center
1168
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Emory Winship Cancer Center
803
mi
from
Atlanta, GA
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Emory Winship Cancer Center
803
mi
from
Atlanta, GA
Click here to add this to my saved trials
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
414
mi
from
Saint Louis, MO
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
414
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Rutgers Cancer Institute of New Jersey
1263
mi
from
New Brunswick, NJ
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Rutgers Cancer Institute of New Jersey
1263
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Roswell Park Cancer Institute
1057
mi
from
Buffalo, NY
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Roswell Park Cancer Institute
1057
mi
from
Buffalo, NY
Click here to add this to my saved trials
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Duke University School of Medicine
1052
mi
from
Durham, NC
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Duke University School of Medicine
1052
mi
from
Durham, NC
Click here to add this to my saved trials